[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100599164":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":11,"locations":28,"responsibleParty":47,"collaborators":11,"id":49,"slug":11,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":11,"eligibilityCriteria":54,"healthyVolunteers":50,"sex":55,"minAge":56,"maxAge":11,"enrollmentInfo":57,"targetDuration":11,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":31,"whyStopped":11,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"5% Minoxidil Foam","EXPERIMENTAL",null,[13],"Drug: 5% minoxidil foam",{"label":15,"type":16,"description":11,"interventionNames":17},"Placebo for 5% Minoxidil Foam","PLACEBO_COMPARATOR",[18],"Drug: Placebo for 5% Minoxidil Foam",[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":11},"DRUG","5% minoxidil foam","Trial participants applied 5% minoxidil foam topically once daily (QD) in the morning or evening, with a maximum daily dose not exceeding 1 g, for up to 24 weeks.",[9],{"type":21,"name":15,"description":26,"armGroupLabels":27,"otherNames":11},"Trial participants applied placebo once daily (QD) in the morning or evening, with a maximum daily dose not exceeding 1 g, for up to 24 weeks.",[15],[29],{"facility":30,"status":31,"city":32,"state":11,"zip":11,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"Beijing, China","RECRUITING","Beijing","China","CN",{"type":36,"coordinates":37},"Point",[38,39],116.39723,39.9075,{"lat":39,"lon":38},[42],{"name":43,"role":44,"phone":45,"phoneExt":11,"email":46},"Linyu Zhu","CONTACT","18013840514","zhulinyu@wsh.3sbio.com",{"type":48,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100599164",false,"NCT07080931","Efficacy and Safety of 5% Minoxidil Foam in Female Androgenetic Alopecia","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study on the Efficacy and Safety of 5% Minoxidil Foam in the Treatment of Female Androgenetic Alopecia","Inclusion Criteria:\n\n* Voluntarily participate in the study and be able to provide a written Informed Consent Form (ICF);\n* Female aged ≥ 18 years;\n* Investigator-diagnosed androgenetic alopecia;\n* Hair loss severity graded D3 to D6 on the Savin scale;\n* Willingness to maintain identical hairstyle, hair color, and hair length at each follow-up visit;\n* No pregnancy plans during the study and for 3 months post-last dose, with commitment to highly effective contraception. Women of childbearing potential must have negative serum pregnancy test ≤7 days prior to first investigational product administration\n\nExclusion Criteria:\n\n* Trial participants with known hypersensitivity to minoxidil or any excipient of the investigational product.\n* Trial participants with known hair loss disorders other than androgenetic alopecia (AGA)\n* Trial participants with any scalp disorder at screening that may interfere with efficacy evaluation, as determined by the investigator.\n* Lactating women\n* Trial participants with history of hypotension or uncontrolled hypertension\n* Trial participants with clinically significant abnormal laboratory findings at screening that may compromise efficacy and safety assessments, as determined by the investigator.\n* Trial participants with clinically significant ECG abnormalities at screening\n* Trial participants with history of malignancy prior to screening.\n* Trial participants known to have conditions or disorders that may affect hair growth or compromise study results.\n* Trial participants with history of using systemically administered therapeutic drugs prior to screening that may interfere with efficacy evaluation, etc.\n* Trial participants with history of topical minoxidil application to alopecia-affected areas prior to screening.\n* Trial participants with no response to prior minoxidil treatment for alopecia\n* Trial participants with history of 5α-reductase inhibitor use prior to screening.\n* Trial participants with history of spironolactone or cyproterone treatment prior to screening.\n* Trial participants with history of autologous platelet-rich plasma (PRP) administration prior to screening.\n* Trial participants with history of chemotherapy, cytotoxic agents, scalp radiation, and\u002For low-level laser therapy (LLLT) or surgical scalp procedures for FAGA prior to screening.\n* Trial participants with history of using medical shampoos or solutions containing ingredients or other components that may interfere with efficacy evaluation prior to screening.\n* Trial participants planning hair transplantation during the study period, or using hair weaving, non-breathable wigs, or hair bonding during treatment.\n* Trial participants in other interventional clinical trials within 3 months before screening (excluding non-interventional studies and screen failures) , or planned concurrent clinical trial enrollment.\n* Trial participants with history of major surgery within 3 months before screening or planning major surgery during the study period.\n* Trial participants deemed by the investigator to have other conditions that may compromise compliance or render them unsuitable for the study.","FEMALE","18 Years",{"count":58,"type":59},294,"ESTIMATED","INTERVENTIONAL",[62],"PHASE3","The primary objective of this study is to evaluate the efficacy of once-daily 5% minoxidil foam versus placebo in female androgenetic alopecia, using the Target Area Terminal Hair Count (TAHC) as the primary endpoint.",[65],"Androgenetic Alopecia",[65],"2026-03-03",{"date":69,"type":70},"2026-03-05","ACTUAL",{"date":72,"type":70},"2025-02-24",{"date":74,"type":59},"2027-12",{"name":5,"class":6},1]